TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30838382

Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thoracic surgery (VATS)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: VATS
Number of subjects: 206
Study: 27783276

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years, with PSL starting at 40 mg/day and tapering, and MZR given once-a-day at 150 mg (group 1) or 3-times-a-day at 50 mg (group 2).
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR) combined with prednisolone (PSL) administered for 2 years.
Number of subjects: 37
Study: 26392095

Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF) + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor (G-CSF)
Number of subjects: 206
Study: 24071924

Group type: EXPERIMENTAL
Intervention: Manual movement observation condition (MovOb)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Nonobservation condition (NonOb)
Number of subjects: 98
Study: 21816786

Group type: EXPERIMENTAL
Intervention: GW501516 (2.5 mg/d)
Number of subjects: 13
Study: 19688104

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 0
Study: 17023230

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 20 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 40 mg
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Carvedilol CR 80 mg
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 15292386

Group type: EXPERIMENTAL
Intervention: Epirubicin-paclitaxel (ET) chemotherapy
Number of subjects: 297

Group type: COMPARATOR
Intervention: Epirubicin-cyclophosphamide (EC) chemotherapy
Number of subjects: 297
Study: 11356585

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9146779

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin 6 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin 1 mg/kg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (both dosages)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin
Number of subjects: 6
Study: 8190679

Group type: EXPERIMENTAL
Intervention: 10 mg of oral ketorolac
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 5 mg of IM morphine
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 10 mg of IM morphine
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 3372704

Group type: EXPERIMENTAL
Intervention: Isocarboxazid
Number of subjects: 56
Study: 31667935

Group type: EXPERIMENTAL
Intervention: Repetitive Peripheral Magnetic Stimulation (rPMS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Head lift exercises
Number of subjects: 24
Study: 30091317

Group type: EXPERIMENTAL
Intervention: Early targeted physical rehabilitation with standard sepsis treatment during hospitalization
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard sepsis treatment
Number of subjects: 40
Study: 27235957

Group type: EXPERIMENTAL
Intervention: Background music
Number of subjects: 159
Study: 23767987

Group type: EXPERIMENTAL
Intervention: Mindfulness with Metta Training Program (MMTP) retreat
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 24137215

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.2‐0.5 μg/kg/h continuous intravenous infusion for 12 h)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Physiological saline and isopropylphenol (2‐4 mg/kg/h intravenous infusion for postoperative sedation)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (saline and isopropylphenol)
Number of subjects: 162
Study: 21562445

Group type: EXPERIMENTAL
Intervention: Intravenous procaine (2 g/24 h) for 72 hours
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19485592

Group type: EXPERIMENTAL
Intervention: Family-based cognitive-behavioral treatment (FCBT; N = 47) with exposure tasks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Family education, support, and attention (FESA; N = 39)
Number of subjects: 86
Study: 16820589

Group type: EXPERIMENTAL
Intervention: Statin (pravastatin 40 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AT1 blockade (irbesartan 150 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of statin and AT1 blocker (same dosages)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (without inhibition of renin‐angiotensin system or statin)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Statin, AT1 blocker, and their combination
Number of subjects: 60
Study: 12759324

Group type: EXPERIMENTAL
Intervention: Combination therapy with hormone replacement (conjugated equine estrogen, 0.625 mg/d, with or without medroxyprogesterone, 2.5 mg/d) and alendronate (10 mg daily)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Alendronate alone (10 mg daily)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Hormone replacement therapy alone
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Combination therapy with hormone replacement and alendronate
Number of subjects: 373

Group type: COMPARATOR
Intervention: All therapies (combination, alendronate, hormone replacement)
Number of subjects: 373
Study: 11317168

Group type: EXPERIMENTAL
Intervention: Viscum album praeparatum mali (Iscador M)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Viscum album praeparatum pini (Iscador P)
Number of subjects: 92
Study: 9117313

Group type: EXPERIMENTAL
Intervention: Proctolog (trimebutine suppository) applied immediately after haemorrhoidectomy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no suppository)
Number of subjects: 160
Study: 8420520

Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo anesthesia (Vaseline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Xylocaine (lidocaine) anesthesia
Number of subjects: 10
Study: 2445114

Group type: EXPERIMENTAL
Intervention: dicumarol
Number of subjects: 88

Group type: COMPARATOR
Intervention: no anticoagulant treatment (control)
Number of subjects: 88
Study: 28514231

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) combined with knee joint mobilization
Number of subjects: 44

Group type: COMPARATOR
Intervention: Biomedical education with knee joint mobilization
Number of subjects: 44
Study: 27043264

Group type: EXPERIMENTAL
Intervention: 7-week outpatient-based exercise and education program
Number of subjects: 63

Group type: COMPARATOR
Intervention: No intervention (Control Group)
Number of subjects: 63
Study: 25012288

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study: 23437933

Group type: EXPERIMENTAL
Intervention: Mailed intervention
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 1483

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1483

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1483
Study: 16200817

Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg once daily, with fluticasone propionate‐salmeterol, 250 microg twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, with fluticasone propionate‐salmeterol, 250 microg twice daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fexofenadine, 180 mg once daily, with fluticasone propionate alone, 250 microg twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo, with fluticasone propionate alone, 250 microg twice daily
Number of subjects: 14
Study: 12742470

Group type: EXPERIMENTAL
Intervention: Full-dose cyclosporine, fixed-dose sirolimus, and corticosteroids
Number of subjects: 771

Group type: COMPARATOR
Intervention: Reduced-dose cyclosporine and trough concentration controlled sirolimus with corticosteroids
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Sirolimus and steroids without calcineurin inhibitors
Number of subjects: 771
Study: 9862578

Group type: EXPERIMENTAL
Intervention: Cathepsin D positivity in oestrogen receptor-positive cases (57%)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cath D levels in Cath D-positive tumour epithelial cells
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 5-year overall survival rate in Cath D-positive patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Time to progression based on Cath D content
Number of subjects: 162
Study: 8588793

Group type: EXPERIMENTAL
Intervention: Horizontal motion (condition A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vertical motion (condition B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position with vertical motion (condition C)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mean motion exposure times for moderate nausea in Experiment 1: A) 9.0 min.; B) 22.4 min.;
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mean motion exposure times for moderate nausea in Experiment 2: A) 15.3 min.; B) 27.1 min.; C) 22.5 min.
Number of subjects: 40
Study: 2212026

Group type: EXPERIMENTAL
Intervention: Conventional estimation of maxillary repositioning in the osteotomy line (Group I)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Measurements from a bone mark on the forehead to the incisor edges (Group II)
Number of subjects: 24
Study: 484501

Group type: EXPERIMENTAL
Intervention: Oral quinidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31918761

Group type: EXPERIMENTAL
Intervention: Nutritional formula containing exogenous ketones (beta-hydroxybutyrate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27068845

Group type: EXPERIMENTAL
Intervention: Composite STSG over ADM
Number of subjects: 52

Group type: COMPARATOR
Intervention: STSG alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 24472436

Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1441
Study: 23103596

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 25 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 50 mg
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride 100 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (starch tablet)
Number of subjects: 300
Study: 19944891

Group type: EXPERIMENTAL
Intervention: Azithromycin extended release (2-g single dose)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (875 mg/125 mg every 12 hours for 10 days)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Azithromycin extended release
Number of subjects: 749

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 749
Study: 19043151

Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy (CAT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Manualised Good Clinical Care (GCC)
Number of subjects: 86
Study: 16000669

Group type: EXPERIMENTAL
Intervention: Cordless screwdriver and FM Extractor
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cordless screwdriver and Trainer's Angel
Number of subjects: 19

Group type: COMPARATOR
Intervention: Cutting tools
Number of subjects: 19
Study: 12501873

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once daily
Number of subjects: 364

Group type: COMPARATOR
Intervention: Ceftriaxone 1 g once daily
Number of subjects: 364
Study: 10511784

Group type: EXPERIMENTAL
Intervention: TIVA (propofol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: IA (halothane)
Number of subjects: 40
Study: 7788230

Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced TurboFLASH (DCETF) imaging
Number of subjects: 41

Group type: COMPARATOR
Intervention: T2 weighted spin echo (T2WSE) imaging
Number of subjects: 41
Study: 2343722

Group type: EXPERIMENTAL
Intervention: droperidol 0.075 mg/kg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: dixyrazine 0.25 mg/kg
Number of subjects: 61

Group type: COMPARATOR
Intervention: no antiemetic prophylaxis (control)
Number of subjects: 61
Study: 7429342

Group type: EXPERIMENTAL
Intervention: Cimetidine (20 mg/kg body weight/24 h)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (15 g/m2/24 h)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pancreatic supplement (Pancrelipase, 27 capsules per day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and sodium bicarbonate
Number of subjects: 15
Study: 31604621

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Povidone-iodine (PVP-I)
Number of subjects: 279
Study: 31594719

Group type: EXPERIMENTAL
Intervention: Microdose (100 μg) of atorvastatin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Therapeutic dose (10 mg) of atorvastatin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 47
Study: 27246653

Group type: EXPERIMENTAL
Intervention: Yoga intervention (32 sessions)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control (physical education as usual)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 211
Study: 25583256

Group type: EXPERIMENTAL
Intervention: C1-esterase-inhibitor (C1-INH) administered at 1,000 international units (IU) intravenously
Number of subjects: 57

Group type: COMPARATOR
Intervention: Corticosteroids and antihistamines (historical control)
Number of subjects: 57
Study: 24164846

Group type: EXPERIMENTAL
Intervention: Sesame group (40 g/day sesame by oral administration for 2 months)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study: 21129058

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 62

Group type: COMPARATOR
Intervention: FGAs
Number of subjects: 62
Study: 19690579

Group type: EXPERIMENTAL
Intervention: Short interval (tests on consecutive days)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Long interval (tests spread over 20-30 days with 5-10 days between tests)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Long interval (tests spread over 20-30 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: First test
Number of subjects: 15
Study: 17546381

Group type: EXPERIMENTAL
Intervention: Chemomechanical carious removal
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional rotary instrument
Number of subjects: 90
Study: 14749545

Group type: EXPERIMENTAL
Intervention: Erlang model for CsA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bayesian estimation using Erlang model
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison with other models (time-lag, zero-order, first-order, Weibull)
Number of subjects: 80
Study: 11380323

Group type: COMPARATOR
Intervention: Pantoprazole, clarithromycin and metronidazole (PCM)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Pantoprazole, clarithromycin and eicosapen (PCE)
Number of subjects: 199
Study: 9916901

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 12
Study: 7995010

Group type: EXPERIMENTAL
Intervention: 7-day nicorandil (10 mg orally twice a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 7-day intermittent nitroglycerin patch (10 mg for 16 of 24 hours)
Number of subjects: 12
Study: 2662829

Group type: EXPERIMENTAL
Intervention: Ketanserin 80 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pentoxiphylline 1,200 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 4919019

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 0
Study: 29939049

Group type: EXPERIMENTAL
Intervention: Interim buprenorphine treatment (IBT; n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control (WLC; n = 25)
Number of subjects: 50
Study: 28043055

Group type: EXPERIMENTAL
Intervention: Power training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Detraining
Number of subjects: 29

Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 29
Study: 26682747

Group type: EXPERIMENTAL
Intervention: GH(67) 67 μg/kg/day (once daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: GH(33) 33 μg/kg/day (once daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: GH(33x2) 33 μg/kg/day (divided into two daily injections)
Number of subjects: 104
Study: 22688433

Group type: EXPERIMENTAL
Intervention: Computer-based navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer navigation at transfer test
Number of subjects: 0
Study: 21575292

Group type: EXPERIMENTAL
Intervention: 2EHRZ/6HE regimen (daily EMB, INH, RMP, and PZA for 2 months, followed by EMB+INH for 6 months)
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: 2(EHRZ)(3)/6HE regimen (same drugs in the intensive phase but given three times weekly, followed by daily EMB+INH for 6 months)
Number of subjects: 1355

Group type: COMPARATOR
Intervention: 2EHRZ/4HR regimen (same intensive phase as in regimen 1, followed by 4 months of daily RMP+INH)
Number of subjects: 1355
Study: 18291010

Group type: EXPERIMENTAL
Intervention: Care sought outside the home
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Care sought from a doctor or hospital
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Traditional medicine as first-line treatment
Number of subjects: 2878

Group type: EXPERIMENTAL
Intervention: Barriers to care seeking
Number of subjects: 2878
Study: 16784035

Group type: EXPERIMENTAL
Intervention: Novel technique using jejunal serosa for pancreatic stump closure (n=23)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional method using stapler and handsewn suturing (n=27)
Number of subjects: 50
Study: 14505898

Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 330

Group type: COMPARATOR
Intervention: DTPw vaccine
Number of subjects: 330
Study: 11022777

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD), 20 mg bid
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 8774026

Group type: EXPERIMENTAL
Intervention: CardioGlide
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CrossWalk
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: treadmill
Number of subjects: 67
Study: 1611143

Group type: EXPERIMENTAL
Intervention: Cyclosporine (10 mg/kg/day, single daily dose)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6322987

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and cisplatin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Methotrexate, doxorubicin, cyclophosphamide, and lomustine
Number of subjects: 106
Study: 31623621

Group type: EXPERIMENTAL
Intervention: Firocoxib
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PCSO-524
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of firocoxib and PCSO-524
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (PCSO-524)
Number of subjects: 79
Study: 29546306

Group type: EXPERIMENTAL
Intervention: Tubaramure program (T24) - food rations for the first 1000 days, BCC
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: Tubaramure program (T18) - food rations from pregnancy through 18 months, BCC
Number of subjects: 3550

Group type: EXPERIMENTAL
Intervention: Tubaramure program (TNFP) - no food during pregnancy, food rations from birth through 24 months, BCC
Number of subjects: 3550

Group type: COMPARATOR
Intervention: Control group - no food rations or BCC
Number of subjects: 3550
Study: 26654115

Group type: EXPERIMENTAL
Intervention: CIT-S (Culturally Informed Therapy)
Number of subjects: 113

Group type: COMPARATOR
Intervention: PSY-ED (Psychoeducation)
Number of subjects: 113
Study: 25626655

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZ) 500mg/day for 20 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Meglumine antimoniate (MA) 15mg/kg/day up to 1,215mg for 20 days
Number of subjects: 24
Study: 22571902

Group type: EXPERIMENTAL
Intervention: Low-dose peginterferon-alfa-2a (PEG-IFN)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 186
Study: 19799627

Group type: EXPERIMENTAL
Intervention: hydroxyurea and l-carnitine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: hydroxyurea and magnesium chloride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: hydroxyurea, l-carnitine and magnesium chloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: hydroxyurea alone
Number of subjects: 120
Study: 17662787

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative
Number of subjects: 30
Study: 16261883

Group type: EXPERIMENTAL
Intervention: Defibrase 15 U plus normal saline 250 mL, followed by defibrase 5 U on days 3, 5, 7, and 9
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Defibrase
Number of subjects: 1053
Study: 11999913

Group type: EXPERIMENTAL
Intervention: RHYTHMS adherence enhancement program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline treatment
Number of subjects: 0
Study: 9617677

Group type: EXPERIMENTAL
Intervention: Allogenic bone implants (ABI)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Adsorbable gelatine sponge
Number of subjects: 52